Current practices for the prophylaxis against bone mineral density loss in patients with autoimmune blistering disease treated with corticosteroids: an expert survey

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):e416-e418. doi: 10.1111/jdv.15005. Epub 2018 May 18.

Authors

K T Amber¹, S A Grando^{1

2

3}

Affiliations

¹ Department of Dermatology, University of California Irvine, Irvine, CA, USA.
² Institute for Immunology, University of California, Irvine, CA, USA.
³ Department of Biological Chemistry, University of California, Irvine, CA, USA.

PMID: 29705983
DOI: 10.1111/jdv.15005

No abstract available

Publication types

Letter

MeSH terms

Adrenal Cortex Hormones / adverse effects*
Adrenal Cortex Hormones / therapeutic use
Bone Density
Bone Density Conservation Agents / therapeutic use*
Humans
Osteoporosis / chemically induced*
Osteoporosis / prevention & control*
Pemphigus / drug therapy*
Practice Guidelines as Topic
Practice Patterns, Physicians'*
Surveys and Questionnaires

Substances

Adrenal Cortex Hormones
Bone Density Conservation Agents